Synthetic cannabinoids 2015: An update for pediatricians in clinical practice

被引:1
|
作者
Daniel Castellanos [1 ]
Leonard M Gralnik [1 ]
机构
[1] Department of Psychiatry and Behavioral Health, Herbert Wertheim College of Medicine, Florida International University
关键词
Synthetic; Cannabinoids; Youth; Children Adolescents;
D O I
暂无
中图分类号
R749.6 [中毒性精神障碍];
学科分类号
100205 ;
摘要
Synthetic cannabinoids are a group of substances in the world of designer drugs that have become increasingly popular over the past few years. Synthetic cannabinoids are a chemically diverse group of compounds functionally similar to THC. Since first appearing on the world market a few years ago these compounds have evolved rapidly. Newer more potent analogues have been developed. Identifying youth who abuse these substances can be difficult. Newer forms of consumption have also evolved. These products are now manufactured in products that look like natural cannabis resin and in liquid cartridges used in electronic cigarettes. Synthetic cannabinoids appear to be associated with potentially dangerous health effects that are more severe than that of marijuana. Some synthetic cannabinoid compounds have been associated with serious physical consequences, such as, seizures, myocardial infarction and renal damage. In addition, psychoactive effects, such as aggression, confusion, anxiety and psychosis have also been reported. The diagnosis remains primarily clinical with toxicological confirmation difficult due to manufacturers constantly developing new analogues to avoid detection. Pediatricians are urged to familiarize themselves with these drugs and the typical presentations of patients who use them.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 50 条
  • [31] Anaphylaxis-a practice parameter update 2015
    Lieberman, Phillip
    Nicklas, Richard A.
    Randolph, Christopher
    Oppenheimer, John
    Bernstein, David
    Bernstein, Jonathan
    Ellis, Anne
    Golden, David B. K.
    Greenberger, Paul
    Kemp, Steven
    Khan, David
    Ledford, Dennis
    Lieberman, Jay
    Metcalfe, Dean
    Nowak-Wegrzyn, Anna
    Sicherer, Scott
    Wallace, Dana
    Blessing-Moore, Joann
    Lang, David
    Portnoy, Jay M.
    Schuller, Diane
    Spector, Sheldon
    Tilles, Stephen A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : 341 - 384
  • [32] Severe Illness Associated with Reported Use of Synthetic Cannabinoids - Mississippi, April 2015
    Kasper, Amelia M.
    Ridpath, Alison D.
    Arnold, Justin K.
    Chatham-Stephens, Kevin
    Morrison, Melissa
    Olayinka, Olaniyi
    Parker, Christina
    Galli, Robert
    Cox, Robert
    Preacely, Nykiconia
    Anderson, Jannifer
    Kyle, Patrick B.
    Gerona, Roy
    Martin, Colleen
    Schier, Josh
    Wolkin, Amy
    Dobbs, Thomas
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2015, 64 (39): : 1121 - 1122
  • [33] Update on colistin in clinical practice
    Alfahad, Wafa A.
    Omrani, Ali S.
    SAUDI MEDICAL JOURNAL, 2014, 35 (01) : 9 - 19
  • [34] Ten reasons to consider cannabinoids in everyday clinical practice
    Lewandowska, Agata
    Graczyk, Michal
    PALLIATIVE MEDICINE IN PRACTICE, 2022, 16 (03): : 167 - 182
  • [35] An Update on Diets in Clinical Practice
    Zupec-Kania, Beth
    Neal, Elizabeth
    Schultz, Rebecca
    Roan, Marian E.
    Turner, Zahava
    Welborn, Michelle
    JOURNAL OF CHILD NEUROLOGY, 2013, 28 (08) : 1015 - 1026
  • [36] Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology
    Schaefer, Nadine
    Wojtyniak, Jan-Georg
    Kettner, Mattias
    Schlote, Julia
    Laschke, Matthias W.
    Ewald, Andreas H.
    Lehr, Thorsten
    Menger, Michael D.
    Maurer, Hans H.
    Schmidt, Peter H.
    TOXICOLOGY LETTERS, 2016, 253 : 7 - 16
  • [37] Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids
    Sholler, Dennis J.
    Huestis, Marilyn A.
    Amendolara, Benjamin
    Vandrey, Ryan
    Cooper, Ziva D.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2020, 199
  • [38] Clinical variants of psychopathological disorders in users of synthetic cannabinoids (spices)
    Bokhan, N.
    Selivanov, G. Y.
    EUROPEAN PSYCHIATRY, 2017, 41 : S199 - S200
  • [39] Clinical and toxicological findings of acute intoxication with synthetic cannabinoids and cathinones
    Fujita, Yuji
    Koeda, Atsuhiko
    Fujino, Yasuhisa
    Onodera, Makoto
    Kikuchi, Satoshi
    Niitsu, Hisae
    Iwasaki, Yasumasa
    Usui, Kiyotaka
    Inoue, Yoshihiro
    ACUTE MEDICINE & SURGERY, 2016, 3 (03): : 230 - 236
  • [40] Synthetic cannabinoids: A review of the clinical implications of a new drug of choice
    Freund, Shaina A.
    Banning, Adrian S.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2017, 30 (11):